HI
NVCR icon

HBK Investments’s NovoCure NVCR Stock Holding History

HBK Investments’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,000
Closed -$1.35M – 779
2021
Q4 		$1.35M Hold
18,000
– – 0.01% 455
2021
Q3 		$2.09M Hold
18,000
– – 0.01% 440
2021
Q2 		$3.99M Buy
+18,000
New +$3.5M 0.01% 354

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HBK Investments's NVCR Position: Q2 2019 in Review

HBK Investments sold out of NovoCure (NVCR) in Q2 2019, closing a stake of 14,970 shares — an estimated $721K sold.

HBK Investments first reported a position in NVCR in Q3 2018 and held it in 2 quarters. The position peaked at $2.94M in Q3 2018. 197 funds tracked by Wall St. Rank hold NVCR as of Q2 2019.

  • HBK Investments reported no remaining NovoCure position as of Q2 2019 after selling out during the quarter.
  • HBK Investments sold 14,970 NovoCure shares in Q2 2019, an estimated $721K.
  • HBK Investments first reported a position in NovoCure in Q3 2018 and held it in 2 quarters.
  • HBK Investments's NovoCure position peaked at $2.94M in Q3 2018.
  • 197 funds tracked by Wall St. Rank held NovoCure as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.